Anastrozole Tablet, Coated
Product Images NDC 68001-155

8 FDA label images from Bluepoint Laboratories · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 68001-155). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Anastrozole Structural Formula (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 01)

Anastrozole Structural Formula (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 01)
Chemical structure of Anastrozole, depicting its molecular formula with a triazole ring attached to a benzene ring substituted with nitrile groups and methyl groups.*
FDA Label Image

Figure 1 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 02)

Figure 1 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 02)
A Kaplan-Meier survival curve graph comparing disease-free survival in months between two treatments, anastrozole and tamoxifen. The y-axis represents the proportion of patients alive and disease-free, while the x-axis shows time in months up to 90 months. Lines for both treatments slightly decline over time, with the number of patients at risk listed below the x-axis for each treatment at various time points.*
FDA Label Image

Figure 2 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 03)

Figure 2 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 03)
A Kaplan-Meier curve graph displaying disease-free survival over months for patients treated with anastrozole versus tamoxifen. The x-axis shows disease-free survival time in months, and the y-axis shows the proportion of patients alive and disease-free. Two survival curves are shown: a dashed line for anastrozole and a solid line for tamoxifen, with patient risk numbers listed at intervals along the x-axis.*
FDA Label Image

Figure 3 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 04)

Figure 3 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 04)
A Kaplan Meier survival curve chart comparing disease-free survival for patients randomized to Anastrozole or Tamoxifen monotherapy over a 120-month period. The vertical axis shows the proportion event-free from 0.50 to 1.00, and the horizontal axis represents time to event in months. The chart includes the number of patients at risk at various time points for each treatment group and specifies that the vertical axis is truncated to enhance clarity.*
FDA Label Image

Figure 4 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 05)

Figure 4 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 05)
Kaplan-Meier survival curve titled 'Disease-Free Survival for Hormone Receptor-Positive Subpopulation of Patients Randomized to Anastrozole or Tamoxifen Monotherapy in the ATAC Trial.' The y-axis shows the proportion event-free, and the x-axis shows time to event in months up to 120. Two lines depict randomized treatments: a solid line for Anastrozole and a dashed line for Tamoxifen. Below the graph is a table showing the number of patients at risk at various time points for each treatment group.*
FDA Label Image

Figure 5 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 06)

Figure 5 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 06)
A Kaplan-Meier survival curve chart comparing time to progression (months) for Anastrozole and Tamoxifen treatments. The Y-axis shows the proportion of patients not progressing, while the X-axis indicates months of treatment up to 40. Data includes the number of patients at risk over time for both treatments.*
FDA Label Image

Figure 6 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 07)

Figure 6 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 07)
A Kaplan-Meier curve showing the proportion of patients not progressing over time in months for two randomized treatments: Anastrozole and Tamoxifen. The graph tracks progression-free survival with time on the x-axis and the proportion not progressing on the y-axis. The number of patients at risk at various time points is listed below the x-axis.*
FDA Label Image

Anastrozole Labels 0.1mg 30s Rev 0523 (Anastrozole Labels 0.1mg 30s Rev 0523.jpg)

Anastrozole Labels 0.1mg 30s Rev 0523 (Anastrozole Labels 0.1mg 30s Rev 0523.jpg)
Anastrozole Tablets USP 1 mg coated tablets label by BluePoint Laboratories. The label shows the product name, strength 1 mg, a round white tablet imprinted with 'A7', and packaging details including a package size of 30 tablets. It also includes storage instructions, child-resistant packaging information, and manufacturer details (Zydus Lifesciences Ltd., Ahmedabad, India).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.